ABSTRACT
Pranlukast (SB 205312, Ultair, ONO-1078, Onon) was launched in Japan in mid-1995 for the treatment of asthma in adults. It is the first orally active cysteinyl leukotriene receptor antagonist (LTRA) to be used in clinical practice (1). A novel, selective, and potent LTRA, pranlukast binds to the leukotriene D4 (LTD4) receptor, inhibiting cysteinyl leukotriene binding. The chemical formula for pranlukast is C27H23N5O41/2H2O (Fig. 1), and its molecular weight is 490.52.
